Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41
- PMID: 8252810
- PMCID: PMC1534428
- DOI: 10.1111/j.1365-2249.1993.tb08223.x
Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41
Abstract
We have previously demonstrated that HIV envelope gp41 binding to specific antibodies decreases after preincubation of fluid-phase gp41 in normal human serum. This inhibition is proven to be mediated by the classical complement pathway. In this study recombinant gp41 (rgp41) and/or synthetic peptides were preadsorbed to solid phase, and then complement (normal human serum/heated human serum/purified Clq/heated Clq) and anti-gp41 antibodies were added either after each other or simultaneously, and the amounts of bound antibody, and deposited C3b, C4b and Clq were measured. Complement-dependent inhibition of antibody binding to solid-phase rgp41 was found, and Clq seems to be at least partially responsible for this phenomenon. Heating of Clq did not affect this process. Higher amounts of anti-gp41 antibodies significantly and dose-dependently enhanced C4b and C3b fixation to solid-phase rgp41. In the case of synthetic peptides corresponding to the immunodominant region of gp41, significant antibody binding to the solid-phase peptides was also detected, and pretreatment of peptides preadsorbed to solid phase with normal human serum almost totally abolished the antibody binding.
Similar articles
-
Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1.Immunology. 1995 Jun;85(2):184-9. Immunology. 1995. PMID: 7642209 Free PMC article.
-
Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1.Immunobiology. 1995 Jun;193(1):98-113. doi: 10.1016/s0171-2985(11)80158-0. Immunobiology. 1995. PMID: 7590866
-
Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV-1.Mol Immunol. 1997 Aug;34(11):809-16. doi: 10.1016/s0161-5890(97)00097-7. Mol Immunol. 1997. PMID: 9444979
-
[Peptides from the principal neutralizing and CD4-binding domain: similar immunoreactive properties and structure pattern].Vestn Ross Akad Med Nauk. 1992;(9-10):47-52. Vestn Ross Akad Med Nauk. 1992. PMID: 1283721 Review. Russian.
-
Antibody: the flexible adaptor molecule.Trends Biochem Sci. 1990 Feb;15(2):64-9. doi: 10.1016/0968-0004(90)90178-e. Trends Biochem Sci. 1990. PMID: 2186517 Review.
Cited by
-
Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.Pathol Oncol Res. 1997;3(4):296-302. doi: 10.1007/BF02904290. Pathol Oncol Res. 1997. PMID: 11173651
-
The Contribution of Complement Protein C1q in COVID-19 and HIV Infection Comorbid with Preeclampsia: A Review.Int Arch Allergy Immunol. 2022;183(10):1114-1126. doi: 10.1159/000524976. Epub 2022 Jun 3. Int Arch Allergy Immunol. 2022. PMID: 35661665 Free PMC article. Review.
-
Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1.Immunology. 1995 Jun;85(2):184-9. Immunology. 1995. PMID: 7642209 Free PMC article.
-
Enhancing role of complement in HIV infection.Clin Exp Immunol. 1994 Aug;97 Suppl 2(Suppl 2):9-11. doi: 10.1111/j.1365-2249.1994.tb06255.x. Clin Exp Immunol. 1994. PMID: 8070143 Free PMC article. Review. No abstract available.
-
Serologic reactivity of a synthetic peptide from human immunodeficiency virus type 1 gp41 with sera from a Mexican population.Clin Diagn Lab Immunol. 1996 Nov;3(6):651-3. doi: 10.1128/cdli.3.6.651-653.1996. Clin Diagn Lab Immunol. 1996. PMID: 8914754 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous